What is ZVSA's earnings growth forecast for 2025-2025?
(NASDAQ: ZVSA) Zyversa Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.
Zyversa Therapeutics's earnings in 2025 is -$8,843,628.
In 2025, ZVSA is forecast to generate -$220,056,322 in earnings, with the lowest earnings forecast at -$220,056,322 and the highest earnings forecast at -$220,056,322.
What is ZVSA's forecast return on equity (ROE) for 2025-2028?
(NASDAQ: ZVSA) forecast ROE is -111.55%, which is considered weak.
What is ZVSA's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: ZVSA) Zyversa Therapeutics's current Earnings Per Share (EPS) is -$5.16. In 2025, ZVSA's EPS is forecast to hit -$46.10 (min: -$46.10, max: -$46.10).
What is ZVSA's forecast return on assets (ROA) for 2025-2028?
(NASDAQ: ZVSA) forecast ROA is -43.22%, which is lower than the forecast US Biotechnology industry average of 32.43%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.